Online first
Review Article
Published online: 2024-07-12
Heart failure biomarkers in hemodialysis patients
1
, 2, 2, 1
, 2, 2, 1
DOI: 10.5603/cj.92167
Pubmed: 38994825
Abstract
The diagnosis of end-stage renal disease (ESRD) is made when the estimated glomerular filtration rate is less than 15 mL/min/1.73 m2. Most patients with that stage of chronic kidney disease (CKD) are eligible for renal replacement treatment, which includes kidney transplantation, hemodialysis and peritoneal dialysis. It is well recognized that CKD raises the risk of cardiovascular disease and is linked to a higher cardiovascular death rate in this population. Additionally, the largest risk of cardiovascular events is seen in ESRD patients. Heart failure (HF) and dangerous arrhythmias, which are more common in the advanced stages of CKD, are two additional causes of cardiovascular death in addition to atherosclerosis-related complications such as myocardial infarction and stroke. In this review the significance of natriuretic peptides and other HF biomarkers in hemodialysis patients, as tools for cardiovascular risk assessment will be discussed.
Keywords: heart failurehemodialysisbiomarkerchronic kidney diseasenatriuretic peptides
References
- Kidney Disease Improving Global Outcomes Work Group. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl (2011). 2013; 3(1): 91–111.
- Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981): 1975–1982.
- Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016; 12(2): 73–81.
- Ma I, Guo M, Muruve D, et al. Sociodemographic associations with abnormal estimated glomerular filtration rate (eGFR) in a large Canadian city: a cross-sectional observation study. BMC Nephrology. 2018; 19(1): 198.
- Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17): 2154–2169.
- Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80(12): 1258–1270.
- Damman K, Valente MAE, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014; 35(7): 455–469.
- Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007; 18(4): 1307–1315.
- House AA, Wanner C, Sarnak MJ, et al. Conference Participants. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(6): 1304–1317.
- Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015; 36(23): 1437–1444.
- Gohar A, Rutten FH, den Ruijter H, et al. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail. 2019; 21(10): 1219–1227.
- Szczurek W, Gąsior M, Skrzypek M, et al. Factors associated with elevated pulmonary vascular resistance in ambulatory patients with end-stage heart failure accepted for heart transplant. Pol Arch Intern Med. 2020; 130(10): 830–836.
- Galderisi M, Cosyns B, Edvardsen T, et al. 2016–2018 EACVI Scientific Documents Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017; 18(12): 1301–1310.
- Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003; 24(19): 1735–1743.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022; 24(1): 4–131.
- Artunc F, Mueller C, Breidthardt T, et al. Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? Kidney Blood Press Res. 2012; 36(1): 172–181.
- Motiwala SR, Januzzi JJr. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharmacol Ther. 2013; 93: 57–67.
- Vasile VC, Jaffe AS. Natriuretic peptides and analytical barriers. Clin Chem. 2017; 63(1): 50–58.
- Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007; 50(25): 2357–2368.
- Wang L, Liu W, Yu Y, et al. Increased circulating bioactive C-type natriuretic peptide is associated with reduced heart rate variability in patients with chronic kidney disease. BMC Nephrol. 2018; 19(1): 50–56.
- Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res. 2001; 51(3): 429–441.
- Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018; 12: 2.
- Kuwahara K, Nakagawa Y, Nishikimi T. Cutting edge of brain natriuretic peptide (BNP) research: the diversity of BNP immunoreactivity and its clinical relevance. Circ J. 2018; 82(10): 2455–2461.
- Breidthardt T, Kalbermatter S, Socrates T, et al. Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. Eur J Heart Fail. 2011; 13(8): 860–867.
- Tonolo G, McMillan M, Polonia J, et al. Plasma clearance and effects of alpha-hANP infused in patients with end-stage renal failure. Am J Physiol. 1988; 254(6 Pt 2): F895–F899.
- Biollaz J, Callahan LT, Nussberger J, et al. Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. Clin Pharmacol Ther. 1987; 41(6): 671–677.
- Dickey DM, Potter LR. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin Chem. 2011; 57(9): 1272–1278.
- Fu S, Ping P, Zhu Q, et al. Brain natriuretic peptide and its biochemical, analytical, and clinical issues in heart failure: a narrative review. Front Physiol. 2018; 9: 692–699.
- Nishikimi T, Ikeda M, Takeda Y, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart. 2012; 98(2): 152–161.
- Madsen LH, Ladefoged S, Corell P, et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007; 71(6): 548–554.
- Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002; 22(5-6): 437–444.
- Sundqvist S, Larson T, Cauliez B, et al. Clinical value of natriuretic peptides in predicting time to dialysis in stage 4 and 5 chronic kidney disease patients. PLoS One. 2016; 11(8): e0159914.
- Nongnuch A, Panorchan K, Davenport A. Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients. Am J Nephrol. 2014; 40(3): 251–257.
- Sivalingam M, Vilar E, Mathavakkannan S, et al. The role of natriuretic peptides in volume assessment and mortality prediction in haemodialysis patients. BMC Nephrol. 2015; 16: 218–227.
- Sheen V, Bhalla V, Tulua-Tata A, et al. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J. 2007; 153(2): 244.e1–244.e5.
- Sommerer C, Heckele S, Schwenger V, et al. Cardiac biomarkers are influenced by dialysis characteristics. Clin Nephrol. 2007; 68(6): 392–400.
- Breidthardt T, Kalbermatter S, Socrates T, et al. Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. Eur J Heart Fail. 2011; 13(8): 860–867.
- Doust J. Qualification versus validation of biomarkers. Scand J Clin Lab Invest Suppl. 2010; 242: 40–43.
- Yang WL, Fahim M, Johnson DW. Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease. Clin Biochem. 2020; 83: 1–11.
- Hassan K, Hassan S, Anwar S, et al. Predictors of left ventricular hypertrophy and their cutoffs in peritoneal dialysis patients. Int Heart J. 2015; 56(2): 186–191.
- Artunc F, Mueller C, Breidthardt T, et al. Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? Kidney Blood Press Res. 2012; 36(1): 172–181.
- Zoair AM, Abdel-Hafez MA, Mawlana W, et al. Serum levels of N-terminal-pro B-type natriuretic peptide as a diagnostic marker for left ventricular dysfunction in children with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl. 2016; 27(6): 1114–1122.
- Apple FS, Wu AHB, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J. 2002; 144(6): 981–986.
- Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012; 60(23): 2427–2463.
- Mishra RK, Li Y, DeFilippi C, et al. Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis. 2013; 61(5): 701–709.
- Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002; 106(23): 2941–2945.
- Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005; 112(20): 3088–3096.
- Roberts MA, Hare DL, Macmillan N, et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. Ann Clin Biochem. 2009; 46(Pt 4): 291–295.
- National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005; 45: 16–153.
- Wayand D, Baum H, Schätzle G, et al. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000; 46(9): 1345–1350.
- Lippi G, Tessitore N, Montagnana M, et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008; 132(1): 72–76.
- Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007; 53(4): 552–574.
- Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23): 2961–2966.
- Manzano-Fernández S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011; 107(2): 259–267.
- Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016; 106(2): 145–152.
- Obokata M, Sunaga H, Ishida H, et al. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients. Am Heart J. 2016; 179: 29–41.
- Zhang Z, Shen Bo, Cao X, et al. Increased soluble suppression of tumorigenicity 2 level predicts all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. Blood Purif. 2017; 43(1-3): 37–45.
- Mueller T, Gegenhuber A, Kronabethleitner G, et al. Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session. Clin Biochem. 2015; 48(16-17): 1163–1166.
- Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
- Haslett C, Simpson KJ, Sethi T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006; 103(13): 5060–5065.
- Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2): 288–298.
- Zhang T, Cao S, Yang H, et al. Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol. 2019; 51(6): 1005–1011.
- Salib M, Girerd S, Girerd N, et al. Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clin Res Cardiol. 2022; 111(6): 614–626.
- Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep. 2012; 9(4): 337–345.
- Breit SN, Johnen H, Cook AD, et al. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011; 29(5): 187–195.
- Schlittenhardt D, Schober A, Strelau J, et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318(2): 325–333.
- Rohatgi A, Patel P, Das SR, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem. 2012; 58(1): 172–182.
- You AS, Kalantar-Zadeh K, Lerner L, et al. Association of growth differentiation factor 15 with mortality in a prospective hemodialysis cohort. Cardiorenal Med. 2017; 7(2): 158–168.
- Breit SN, Carrero JJ, Tsai VWW, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant. 2012; 27(1): 70–75.
- Lee EJ, Hwang HB, Han SH, et al. Serum growth differentiation factor-15/albumin ratio as a 2-year survival marker of end-stage renal disease patients initiating maintenance hemodialysis. Diagnostics (Basel). 2022; 12(2).
- Lichtenauer M, Jirak P, Wernly B, et al. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med. 2017; 44(7): 31–38.
- Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail. 2007; 13(2): 120–127.
- Collister D, Mazzetti A, Bhalerao A, et al. Variability in cardiac biomarkers during hemodialysis: a prospective cohort study. Clin Chem. 2021; 67(1): 308–316.
